Tough Road Lies Ahead For Proposed Biologics Bill

Law360, New York (June 25, 2007, 12:00 AM EDT) -- A U.S. Senate committee will consider a compromise version of legislation that would give the U.S. Food and Drug Administration a way to approve generic or follow-on biologic drugs on Wednesday.

The Senate Health, Education, Labor and Pensions Committee is scheduled to address the legislation, named the Biologics Price Competition and Innovation Act of 2007. The bill was hammered out as a compromise late Friday by Sens. Edward Kennedy (D-Mass.), Orrin Hatch (R-Utah), Hillary Clinton (D-N.Y.) and Mike Enzi (R-Wyo.).

The proposed legislation attempts to find...
To view the full article, register now.